US 2003/0195205 A1 · PDE9 inhibitors for treating cardiovascular disorders

Abstract

The invention relates to PDE9 inhibitors for treating cardiovascular disorders. Preferred PDE9 inhibitors are compounds of formula I wherein R1 is H or C1-6 alkyl, wherein R1 is attached to either N1 or N2; R2 is C1-6 alkyl optionally substituted by hydroxy or alkoxy; C3-7 cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy; a saturated 5-6-membered heterocycle optionally substituted by alkyl, hydroxy or alkoxy; het1 or Ar1; R3 is C1-6 alkyl optionally substituted by 1 or 2 groups independently selected from: Ar2; C3-7cycloalkyl optionally substituted by C1-6alkyl; OAr2; SAr2; NHC(O)C1-6 alkyl; het2; xanthene; and naphthalene. 1

Claims26

Dependent claims

A compound of formula I, a pharmaceutically acceptable salt, solvate or prodrug thereof

45
wherein
R1 is H or C1-6 alkyl, wherein R1 is attached to either N1 or N2;
R2 is C1-6 alkyl optionally substituted by hydroxy or alkoxy;
C3-7 cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy;
a saturated 5-6-membered heterocycle optionally substituted by alkyl, hydroxy or alkoxy;
het1 or Ar1;
R3 is C1-6 alkyl optionally substituted by 1 or 2 groups independently selected from:
Ar2;
C3-7cycloalkyl optionally substituted by C1-6alkyl;
OAr2;
SAr2;
NHC(O)C1-6 alkyl;
het2;
xanthene;
and naphthalene;
wherein Ar1 and Ar2 are independently groups of formula
46
wherein R4, R5 and R6 are independently selected from:
hydrogen, halo, phenoxy, phenyl, CF3, OCF3, R7, SR7 and OR7, wherein R7 is C1-6 alkyl optionally substituted by het3 or by a phenyl group optionally substituted by 1, 2 or 3 groups independently selected from halo, CF3, OCF3, C1-6 alkyl and C1-6 alkoxy;
or wherein R4 and R5 combine to form a 3 or 4 atom link, wherein said link may incorporate one or two heteroatoms independently selected from O, S and N;
and
wherein het1, het2 and het3, which may be the same or different, are aromatic 5-6 membered heterocycles containing 1, 2 or 3 heteroatoms, independently selected from O, S and N, said heterocycle optionally substituted by 1, 2 or 3 substituents, independently selected from C1-6 alkyl, C1-6alkoxy, halo and phenyl optionally substituted by 1, 2 or 3 groups independently selected from halo and C1-6 alkyl;
with the provisos that when
a) R1 is attached to N1, R1 is C1-3 alkyl and R2 is propyl then R3 is not methyl substituted by Ar1, and
b) R1 is attached to N1, R1 is C1-6 alkyl and R2 is methyl then R3 is not C1-4alkyl substituted by Ar1.

23 more elements

Dependencies are inferred from the claim text.

PDE9 inhibitors for treating cardiovascular disorders

Life of this patent

PDE9 inhibitors for treating cardiovascular disorders

Life of this patent

Abstract

Claims26